Tags

Type your tag names separated by a space and hit enter

Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis.
Intern Med. 2020; 59(9):1227-1230.IM

Abstract

Liposomal-amphotericin B (L-AmB) is used for cutaneous leishmaniasis (CL); however, its treatment failure has not yet been described in detail. A 58-year-old man returned from the Republic of Venezuela with a cutaneous ulcer on his left lower leg. The causative pathogen was Leishmania braziliensis. We started L-AmB 3 mg/kg/day for 6 days; however, the ulcer did not resolve. The patient was successfully retreated with a higher dose L-AmB 4 mg/kg/day 9 times (total, 36 mg/kg). If L-AmB fails to treat CL and other therapeutics cannot be used, increasing the L-AmB dose is a viable option.

Authors+Show Affiliations

Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.Department of Infectious Diseases and Infection Control, Saitama Medical University, Japan. Center for Clinical Infectious Diseases and Research, Saitama Medical University, Japan.Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.Department of Microbiology, Saitama Medical University, Japan.Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

32378656

Citation

Kosaka, Atsushi, et al. "Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis Due to Leishmania Braziliensis." Internal Medicine (Tokyo, Japan), vol. 59, no. 9, 2020, pp. 1227-1230.
Kosaka A, Sakamoto N, Hikone M, et al. Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis. Intern Med. 2020;59(9):1227-1230.
Kosaka, A., Sakamoto, N., Hikone, M., Imai, K., Ota, M., Washino, T., Maeda, T., & Iwabuchi, S. (2020). Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis. Internal Medicine (Tokyo, Japan), 59(9), 1227-1230. https://doi.org/10.2169/internalmedicine.4096-19
Kosaka A, et al. Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis Due to Leishmania Braziliensis. Intern Med. 2020;59(9):1227-1230. PubMed PMID: 32378656.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis. AU - Kosaka,Atsushi, AU - Sakamoto,Naoya, AU - Hikone,Mayu, AU - Imai,Kazuo, AU - Ota,Masayuki, AU - Washino,Takuya, AU - Maeda,Takuya, AU - Iwabuchi,Sentarou, Y1 - 2020/05/01/ PY - 2020/5/8/entrez PY - 2020/5/8/pubmed PY - 2020/7/31/medline KW - Leishmania braziliensis KW - cutaneous leishmaniasis KW - liposomal-amphotericin B SP - 1227 EP - 1230 JF - Internal medicine (Tokyo, Japan) JO - Intern Med VL - 59 IS - 9 N2 - Liposomal-amphotericin B (L-AmB) is used for cutaneous leishmaniasis (CL); however, its treatment failure has not yet been described in detail. A 58-year-old man returned from the Republic of Venezuela with a cutaneous ulcer on his left lower leg. The causative pathogen was Leishmania braziliensis. We started L-AmB 3 mg/kg/day for 6 days; however, the ulcer did not resolve. The patient was successfully retreated with a higher dose L-AmB 4 mg/kg/day 9 times (total, 36 mg/kg). If L-AmB fails to treat CL and other therapeutics cannot be used, increasing the L-AmB dose is a viable option. SN - 1349-7235 UR - https://www.unboundmedicine.com/medline/citation/32378656/Failure_of_Liposomal_amphotericin_B_Treatment_for_New_World_Cutaneous_Leishmaniasis_due_to_Leishmania_braziliensis_ L2 - https://dx.doi.org/10.2169/internalmedicine.4096-19 DB - PRIME DP - Unbound Medicine ER -